Arrow declarations: which way is the law pointing?

In the life sciences field, patents are fundamental assets for companies developing new technologies and therapeutics. However, the way some companies have prosecuted their patent portfolios has caused issues for those seeking to create new products and therapies in developing fields.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Biotech

Interview: How BlueRock Therapeutics is layering IP in stem cell therapies

13 July 2026 The company’s VP of IP explains how he is protecting the process, staying ahead of outside counsel, and why a biosimilar path is only a matter of time.

Biotech

Merck KGaA agrees $11.3bn deal in major life sciences expansion

26 June 2026 Deal is aimed at strengthening German company’s presence across high-growth life sciences markets by adding a portfolio of advanced research and analytical technologies.

Biotech

Novartis and Eli Lilly sign separate $1.9bn novel drug deals

25 June 2026 Novartis will work with a US biotech company on new cancer therapies, while Lilly has partnered with a Chinese biopharma firm to develop new medicines.

More features

Interview: How BlueRock Therapeutics is layering IP in stem cell therapies

Explaining genetically engineered rodents to a jury—and ultimately beating Amgen

UPC upholds injunction in Invisalign maker’s software dispute with rival

BioNTech and Pfizer secure big European win over mRNA patent

UPC revives patent, but timing sinks Guardant’s appeal

HGF expands European offering with pair of in-house hires

Ashurst Perkins Coie opens its doors following landmark merger

Merck KGaA agrees $11.3bn deal in major life sciences expansion

Arrow declarations: which way is the law pointing?

More on this story

Editor's picks

Editor's picks

More features